Physician profile
Benjamin Stacy
NPI 1093127367
$809.21
in general payments reported to CMS, 2019-2025
13 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.81 · 2020: $93.16 · 2021: $65.11 · 2022: $201 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $417.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $254.96 | 2022-2025 | Austedo Xr, Uzedy |
| Abbvie INC. | $116.16 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $77.08 | 2025 | |
| Allergan, INC. | $62.71 | 2020 | |
| Lundbeck LLC | $60.93 | 2020-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $53.45 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $42.30 | 2025 | Qelbree |
| Alkermes, INC. | $39.57 | 2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $31.76 | 2019-2025 | Abilify Asimtufii, Abilify Maintena |
| Luye Pharma (USA) Ltd. | $26.46 | 2025 | Erzofri Extended-Release |
| Sunovion Pharmaceuticals INC. | $17.89 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.43 | 2021 | |
| Almatica Pharma LLC | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Stacy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.